The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
SISTAQUIT Scale-up In Indigenous Populations In Australia
Funder
National Health and Medical Research Council
Funding Amount
$1,800,000.00
Summary
SISTAQUIT®(Supporting Indigenous Smokers to Assist Quitting) is a research backed training program that provides free, online training in quit smoking methods to health providers. This study aims to expand the SISTAQUIT intervention to all Australian health services that cater to Indigenous women during pregnancy. This research will test numerous methods to implement SISTAQUIT to identify the most effective and economical strategy suitable for roll-out, and build Indigenous workforce capacity.
A Randomised Controlled Trial Of A High Intensity Intervention To Reduce Smoking Among Pregnant Indigenous Women
Funder
National Health and Medical Research Council
Funding Amount
$695,250.00
Summary
The rates of smoking in pregnancy for Indigenous women and passive smoke exposure in Indigenous households are unacceptably high, with 65% smoking during pregnancy. In contrast only about 20% of other Australian women are reported to smoke during pregnancy. However there have been no Australian trials to assess the extent to which Indigenous women can be assisted to quit smoking during pregnancy. This is a clinical trial conducted in Aboriginal and Torres Strait Islander Community Controlled Hea ....The rates of smoking in pregnancy for Indigenous women and passive smoke exposure in Indigenous households are unacceptably high, with 65% smoking during pregnancy. In contrast only about 20% of other Australian women are reported to smoke during pregnancy. However there have been no Australian trials to assess the extent to which Indigenous women can be assisted to quit smoking during pregnancy. This is a clinical trial conducted in Aboriginal and Torres Strait Islander Community Controlled Health Services located in Townsville and Cairns. The trial is designed to show whether an intensive program of smoking cessation advice provided to women and their major family supports can reduce smoking ratesamong Indigenous women in pregnancy. General practitioners, Aboriginal health workers and nurses working in these health services will conduct the study and be trained in how to deliver the support required to assist women quit smoking.Read moreRead less
Yr 4 & 5 Of A Randomised Controlled Trial Of An Intensive Intervention To Reduce Smoking Among Pregnant Indigenous Women
Funder
National Health and Medical Research Council
Funding Amount
$324,665.00
Summary
Rates of smoking in pregnancy are significantly higher among Indigenous women than other Australian women (65% vs 20%). This application is to continue the first ever trial of an intensive program of smoking cessation advice provided to women and their major family supports designed to reduce smoking rates among Indigenous women in pregnancy. This project has already been running sucessfully for two years, however, further funds are required to complete years four and five of the project.
Smoking Cessation For Youth Project Booster And Cohort Tracking Study
Funder
National Health and Medical Research Council
Funding Amount
$135,550.00
Summary
Adolescence is a critical period for the establishment of adult drug use behaviours. If smoking does not commence in teenage years it is unlikely to occur. This innovative project not only continues to address tobacco control with this important age group but also builds on evidence from a randomised intervention trial involving over 4,000 Year 9 students tracked over two years. This project was called the Smoking Cessation for Youth Project (SCYP). Preliminary longitudinal analyses of the SCYP ....Adolescence is a critical period for the establishment of adult drug use behaviours. If smoking does not commence in teenage years it is unlikely to occur. This innovative project not only continues to address tobacco control with this important age group but also builds on evidence from a randomised intervention trial involving over 4,000 Year 9 students tracked over two years. This project was called the Smoking Cessation for Youth Project (SCYP). Preliminary longitudinal analyses of the SCYP data indicate that the intervention students were significantly less likely to smoke heavily (smoking five or more days per week) than the control group and that intervention students were also significantly less likely to have tried smoking than the control group. These results represent a world first in evidence that population-based smoking cessation interventions among teenagers can be successful. The proposed project will determine the extent to which these positive intervention effects are sustainable, two years post intervention, as our cohort moves into Year 12. In addition to tracking the possible decay of SCYP intervention effects, the proposed project will also measure the effects of a booster intervention delivered students when they are in Year 12 (2002). The Year 12 intervention will comprise an innovative self-help 'magazine style' booster and a supportive environmental intervention involving school nurses and local GPs. This proposal represents a cost-effective opportunity to measure the effectiveness of a Year 12 tobacco cessation booster intervention. Further data on tobacco smoking behaviour in 2002 will also enable us to determine how long the SCYP intervention appears to affect behaviour and whether 'boosters' are needed in later secondary school years to maintain the benefits.Read moreRead less
Pharmacotherapy For Smoking Cessation Prior To And During Pregnancy
Funder
National Health and Medical Research Council
Funding Amount
$620,950.00
Summary
This study will examine the effectiveness and safety of medications for smoking cessation prior to and during pregnancy. It will achieve this by linking routinely collected midwives data from NSW and WA to prescriptions records and other health service use. It will explore potential inequalities in the use and effectiveness of these medications in disadvantaged populations, including Aboriginal women, and it will investigate whether their use has changed in response to policy changes.
Antimalarial Drugs In Pregnancy: Preclinical And Clinical Studies Of Conventional And Novel Agents
Funder
National Health and Medical Research Council
Funding Amount
$470,115.00
Summary
Women in malaria-endemic areas such as coastal PNG are at high risk of malaria in pregnancy. To prevent the substantially increased malaria-associated morbidity and mortality in mother and child, and because even asymptomatic infections can be deleterious, there has been a move to giving antimalarial drugs regularly during pregnancy regardless of the mother's clinical or parasitological status. In poor tropical countries, such treatment usually comprises safe and inexpensive agents such as chlor ....Women in malaria-endemic areas such as coastal PNG are at high risk of malaria in pregnancy. To prevent the substantially increased malaria-associated morbidity and mortality in mother and child, and because even asymptomatic infections can be deleterious, there has been a move to giving antimalarial drugs regularly during pregnancy regardless of the mother's clinical or parasitological status. In poor tropical countries, such treatment usually comprises safe and inexpensive agents such as chloroquine and Fansidar. There are two main issues with this approach. First, the efficacy of such conventional agents is waning and this increases the risk of break-through malaria. Second, there are few data on how the drugs are handled in pregnancy on which to base recommendations for treatment. We plan to collect information on the disposition and effectiveness of chloroquine and Fansidar in women with malaria in pregnancy in PNG that should allow a critical appraisal of the usefulness of current regimens in PNG and in other tropical countries where parasite resistance to these agents is emerging. Artemisinin combination therapy (ACT) in the form of a novel artemisinin drug and a longer-acting partner has been suggested as the most promising alternative therapy for malaria in pregnancy if conventional drugs fail. We plan to assess the safety of a leading ACT formulation, namely dihydroartemisinin and the chloroquine-like drug piperaquine (DHA-PQ), in animals before extending our studies to women with malaria in PNG. These latter studies will allow an evaluation of the safety and efficacy of DHA-PQ as novel therapy for malaria in pregnancy in PNG and other tropical countries.Read moreRead less
Unintended Adverse Effects Of Advertising For Nicotine Replacement Therapies
Funder
National Health and Medical Research Council
Funding Amount
$133,250.00
Summary
Advertising for certain pharmaceutical products (nicotine replacement therapy( NRT)) to help people quit smoking has been permitted in Australia since 1997. Zyban, an antidepressant drug, has been found to be helpful in quitting smoking, but advertising has not yet been permitted in Australia although it is allowed overseas. Because such advertising will reach more than the primary target group of heavy smokers ready to quit, it is important to consider the responses of other smokers who are not ....Advertising for certain pharmaceutical products (nicotine replacement therapy( NRT)) to help people quit smoking has been permitted in Australia since 1997. Zyban, an antidepressant drug, has been found to be helpful in quitting smoking, but advertising has not yet been permitted in Australia although it is allowed overseas. Because such advertising will reach more than the primary target group of heavy smokers ready to quit, it is important to consider the responses of other smokers who are not ready to quit and those at risk of taking up smoking. There is concern that there may be 'boomerang' effects, albeit unintended, on these population groups, because they may feel reassured that there is an effective method to quit and so be in no rush to quit soon, they may try to quit using these products before they are really ready, and in the case of teenagers, they may think that these products make it easy to quit, so there is less problem with starting to smoke. In order to assess if this is so, we will randomly allocate smokers not yet ready to quit and teenagers to either (a) a group where they view 3 ads promoting non-drug methods of quitting, such as the Quitline, (b) a group where they view 3 ads promoting the NRT gum or patch, or (c) a group where they view 3 ads promoting Zyban as a method for quitting. The study will use questionnaires to assess whether, compared with those viewing the non-drug anti-smoking ads, those viewing the NRT or Zyban ads think smoking is less addictive and have less intention to quit, or in the case of teenagers, have more intention to take up smoking. This project will be the first formal study to assess whether there may be adverse effects of NRT and Zyban advertising on smokers not yet ready to quit and teenagers who are not already regular smokers. For this reason, the study will help an assessment of the risks of such advertising compared with the established benefits for smokers who are ready to quit.Read moreRead less